PCIA
VKTX icon

Prime Capital Investment Advisors’s Viking Therapeutics VKTX Stock Holding History

Prime Capital Investment Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Buy
11,483
+140
+1% +$4.52K ﹤0.01% 727
2026
Q1 		$369K Buy
11,343
+5,518
+95% +$177K ﹤0.01% 764
2025
Q4 		$205K Buy
+5,825
New +$206K ﹤0.01% 961
2024
Q4 		– Sell
-3,719
Closed -$235K – 973
2024
Q3 		$235K Buy
+3,719
New +$218K ﹤0.01% 807
2024
Q2 		– Sell
-2,578
Closed -$211K – 1039
2024
Q1 		$211K Buy
+2,578
New +$115K ﹤0.01% 912

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Prime Capital Investment Advisors's VKTX Position: Q2 2026 in Review

Prime Capital Investment Advisors increased its Viking Therapeutics (VKTX) stake by 1.2% in Q2 2026, buying an estimated $4.52K and bringing the position to 11,483 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #727.

Prime Capital Investment Advisors first reported a position in VKTX in Q1 2024 and has held it in 5 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Prime Capital Investment Advisors held 11,483 shares of Viking Therapeutics worth $448K as of Q2 2026.
  • Prime Capital Investment Advisors bought 140 Viking Therapeutics shares in Q2 2026, an estimated $4.52K.
  • Viking Therapeutics made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #727 holding.
  • Prime Capital Investment Advisors first reported a position in Viking Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.